ALL FOR VACCINE, VACCINE FOR ALL

Abstract

It has been one year that the world has been hit by COVID 19 pandemic. After facing mortalities and various morbidities, we are in the phase of preparation and administration of vaccine. While developed countries are already in the position of providing the vaccine to majority of their population, developing countries still face lack of resources to vaccinate even their health care workers, as stated by WHO. It is high time for the leadership of the developing nations to come forward and make a coherent plan to tackle this issue. To achieve this "˜Global Solidarity' COVID-19 Vaccines Global Access (COVAX) initiative has been launched with support of WHO and vaccine advocacy groups. Higher Education Commission (HEC) of Pakistan has always encouraged clinical trials in the field of research. As health institutions in Khyber Pakhtunkhwa (KP) province enjoy autonomous status after the promulgation of MTI act, these institutions are now in a better position to execute clinical trials. Phase 3 trial of Sinophorm vaccine was carried out in the clinical trial unit of Shifa College of Medicine3. Although the results have not been peer reviewed and published so far, but the concerned authorities are satisfied with phase 3 results and recommend its emergency usage in front line health workers We need to put the essential elements in their respective places to get our desired results through HEC, Pakistan Medical Commission (PMC), National Health Services (NHS), Drug Regulatory Authority of Pakistan (DRAP) and National Bioethics Committee.